Live Biotherapeutics Drug Discovery Service for Neonatal Necrotizing Enterocolitis (NEC)
Creative Biolabs aims to be the most trusted provider of live biotherapeutics solutions, supporting scientific discovery through high-precision and cost-effective technical services and products for researchers worldwide. Our team is comprised of a passionate group of biologists with a multidisciplinary background who have decades of industry experience and a proven track record in delivering cost-effective living biotherapeutic solutions.
Overview of Necrotizing Enterocolitis (NEC)
NEC is an inflammatory bowel disease that predominantly affects low birth weight infants and preterm infants and is characterized by transmural inflammation and necrosis of the large or small intestine, followed by translocation of gas-forming microorganisms to the intestinal wall. The risk factors for this disease are prematurity, bacterial colonization, enteral feeding, and altered intestinal blood flow, with prematurity itself being the greatest risk factor rather than any particular insult.
Probiotics and NEC
Probiotics have the potential to affect many aspects of the pathway leading to NEC. They affect bacterial colonization and mature gastrointestinal host defense. They protect against mucosal injury, limit the inflammatory response, and have clinically been shown to decrease the incidence of NEC. Probiotics can promote the balance of intestinal flora and enhance intestinal immune function, which has a certain protective effect on neonatal NEC.
The main mechanism by which Bifidobacterium colonizes the gut of full-term infants is the species-specific ability to use HMOs as a food source. In addition to the advantage of colonizing human milk, Bifidobacterium exhibits other properties that may help prevent NEC. In a rat model of NEC, B. infantis reduced the incidence and severity of NEC and decreased the expression of IL6, IL8, TNFα, IL23, and iNOS. In a rat model of NEC, B. bifidum reduced the incidence and severity of NEC, attenuated IL6 induction, attenuated trefoil factor 3 and several antimicrobial peptides induction, improved barrier function, activated TLR2, and reduced apoptosis. B. breve was also tested in rats with reduced NEC incidence and severity.
L. acidophilus is a common food additive that is stable over a range of pH and temperature. L. acidophilus can inhibit the induction of NFκB and IL-8 by platelet-activating factor (PAF), which is an important inflammatory pathway in NEC. L. rhamnosus reduces the incidence and severity of NEC by altering TLR9 signaling in both piglets and mouse models of NEC. L. rhamnosus GG also improved intestinal barrier function.
Next-generation Probiotic Strains at Creative Biolabs
Creative Biolabs can offer a range of next-generation probiotics for live biotherapeutics research, including but not limited to the following, click on Probiotic Strains to check out more strains you might be interested in.
Our Services for the NEC Research
As a contract research service supplier, Creative Biolabs has worked on many clients' projects, including the supply of strain products, the preparation of probiotics for animal gavage experiments, and antibiotic resistance analysis. If you are interested in our service, or you do not find the service you need, you can contact us directly to discuss, because our technology platform is constantly updated, some of them have not been displayed on our website in time.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
